Matches in SemOpenAlex for { <https://semopenalex.org/work/W2000940612> ?p ?o ?g. }
Showing items 1 to 62 of
62
with 100 items per page.
- W2000940612 endingPage "67" @default.
- W2000940612 startingPage "63" @default.
- W2000940612 abstract "Le traitement de l’hypercholestérolémie de l’enfant s’intègre dans le cadre de la prévention de la maladie coronaire prématurée de l’adulte. Le traitement médicamenteux doit donc être ciblé sur les hypercholestérolémies héréditaires, transmises sur le mode autosomique dominant (hypercholestérolémies familiales, déficience familiale en apolipoprotéine B100, dyslipidémie combinée familiale), dont on connaît l’importance du risque cardiovasculaire qui leur est associé chez l’adulte jeune. Au cours de ces affections, les médicaments hypocholestérolémiants sont indiqués chez les enfants dont la concentration plasmatique de LDL-cholestérol reste supérieure à 190 mg/dL après 6 mois de traitement diététique. La colestyramine dont plusieurs études contrôlées ont montré l’efficacité et la bonne tolérance chez l’enfant reste le traitement de première intention. Les statines peuvent être prescrites en relais de la colestyramine à partir de l’âge de 8 à 9 ans mais on manque encore à l’heure actuelle de données sur leur tolérance à long terme. Les fibrates peuvent également être utilisés en seconde intention, mais ils n’ont fait l’objet d’aucune étude contrôlée en pédiatrie. The treatment of hypercholesterolaemia in children is often discussed as part of the primary prevention strategy for premature coronary disease in adults. Cholesterol-lowering drugs are appropriate in children with hereditary autosomal dominant diseases such as familial hypercholesterolaemia, familial Apo B100 deficiency, or combined familial dyslipidaemia. Indeed, these diseases are associated with a high risk of cardiovascular attacks in young adults. In children suffering from these diseases, cholesterol-lowering drugs are considered when the plasma low density-lipoprotein (LDL)-cholesterol concentration remains above 190 mg/dL after a 6-month dietary treatment. The drug of first choice remains bile acid-binding resines (colestyramine) because their efficacy and safety are well documented in children. HMG-CoA reductase inhibitors can be used in children older than 8 or 9 years of age in cases of an altered observance of colestyramine treatment, but their long-term tolerance is unknown. Fibrates are also efficient, however their safety has not been evaluated in controlled studies through in children." @default.
- W2000940612 created "2016-06-24" @default.
- W2000940612 creator A5002685384 @default.
- W2000940612 date "2003-01-01" @default.
- W2000940612 modified "2023-10-16" @default.
- W2000940612 title "Les médicaments hypocholestérolémiants chez l’enfant" @default.
- W2000940612 cites W124875321 @default.
- W2000940612 cites W1855484334 @default.
- W2000940612 cites W1962849007 @default.
- W2000940612 cites W1978343052 @default.
- W2000940612 cites W1979086804 @default.
- W2000940612 cites W1986882958 @default.
- W2000940612 cites W2003694324 @default.
- W2000940612 cites W2009784966 @default.
- W2000940612 cites W2017464081 @default.
- W2000940612 cites W2062366132 @default.
- W2000940612 cites W2094723169 @default.
- W2000940612 cites W2098478434 @default.
- W2000940612 cites W2125639599 @default.
- W2000940612 cites W2155598961 @default.
- W2000940612 cites W2315613231 @default.
- W2000940612 cites W2335129974 @default.
- W2000940612 cites W3153594880 @default.
- W2000940612 doi "https://doi.org/10.2515/therapie:2003009" @default.
- W2000940612 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12822202" @default.
- W2000940612 hasPublicationYear "2003" @default.
- W2000940612 type Work @default.
- W2000940612 sameAs 2000940612 @default.
- W2000940612 citedByCount "3" @default.
- W2000940612 countsByYear W20009406122012 @default.
- W2000940612 crossrefType "journal-article" @default.
- W2000940612 hasAuthorship W2000940612A5002685384 @default.
- W2000940612 hasConcept C126322002 @default.
- W2000940612 hasConcept C29456083 @default.
- W2000940612 hasConcept C3018906752 @default.
- W2000940612 hasConcept C71924100 @default.
- W2000940612 hasConceptScore W2000940612C126322002 @default.
- W2000940612 hasConceptScore W2000940612C29456083 @default.
- W2000940612 hasConceptScore W2000940612C3018906752 @default.
- W2000940612 hasConceptScore W2000940612C71924100 @default.
- W2000940612 hasIssue "1" @default.
- W2000940612 hasLocation W20009406121 @default.
- W2000940612 hasLocation W20009406122 @default.
- W2000940612 hasOpenAccess W2000940612 @default.
- W2000940612 hasPrimaryLocation W20009406121 @default.
- W2000940612 hasRelatedWork W1969186450 @default.
- W2000940612 hasRelatedWork W1984199602 @default.
- W2000940612 hasRelatedWork W1999344589 @default.
- W2000940612 hasRelatedWork W2019135295 @default.
- W2000940612 hasRelatedWork W2094915539 @default.
- W2000940612 hasRelatedWork W2379084044 @default.
- W2000940612 hasRelatedWork W2380152327 @default.
- W2000940612 hasRelatedWork W2781802826 @default.
- W2000940612 hasRelatedWork W2789448498 @default.
- W2000940612 hasRelatedWork W4243666276 @default.
- W2000940612 hasVolume "58" @default.
- W2000940612 isParatext "false" @default.
- W2000940612 isRetracted "false" @default.
- W2000940612 magId "2000940612" @default.
- W2000940612 workType "article" @default.